Safety study of efgartigimod in adults with myasthenia gravis
Observes safety of efgartigimod in adults with generalized myasthenia gravis who take it.
Plain-language title generated from the registry record
Registry title: A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
Key facts
- Where
- Barcelona, Madrid, and Seville, SpainSee the 4 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with generalised myasthenia gravis (gMG). Some will start or have just started efgartigimod. Others have not taken it and are not planned to.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Diagnosed with gMG
- Earlier treatment
- One group is about to start efgartigimod or is in its first cycle. The other group has never taken efgartigimod and is not planned to start it.
Read by machine on 12 November 2026.
Where in Spain
- Hospital Universitari de BellvitgeBarcelona, SpainContact: Carlos Casasnovas, MDTaking people
- Hospital Universitari Vall d'Hebron, Unitat de Malalties Neuromusculars, Servei de NeurologiaBarcelona, SpainContact: Raul Juntas Morales, MDTaking people
- Hospital Clínico Universitario San CarlosMadrid, SpainContact: Lucia Galán Dávila, MDTaking people
- Hospital Universitario Virgen MacarenaSeville, SpainContact: Eva Maria Martinez Fernández, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- argenx
- Trial code
- NCT06298565
- Record updated
- 17 February 2026
- Original description
This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment will be eligible to enroll into the non-efgartigimod cohort.Read full original descriptionShow less
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment will be eligible to enroll into the non-efgartigimod cohort.
Inclusion: Patients diagnosed with gMG who are expected to start commercial efgartigimod at enrolment or who are within their first cycle of efgartigimod at enrolment or Patients diagnosed with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment; Have provided appropriate written informed consent.
Exclusion: None.